The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of […]
PARIS, May 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company’s minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a reduction of tricuspid regurgitation (TR) symptoms – caused by a leaky tricuspid heart valve […]
ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ — Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, the next-generation Confirm Rx™ insertable cardiac monitor (ICM), a paperclip-sized implantable […]
ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when added to current heart disease assessments.1 Using data from the Atherosclerosis […]
ABBOTT PARK, Ill., April 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019. First-quarter worldwide sales of $7.5 billion increased 2.0 percent on a reported basis and 7.1 percent on an organic* basis. Reported diluted EPS from continuing operations under GAAP was $0.38 in the first quarter. […]
NEW ORLEANS, March 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world’s largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint […]
ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery. Supported by the results of the landmark COAPT™ Trial, […]
ABBOTT PARK, Ill., March 6, 2019 /PRNewswire/ — Key medical devices across Abbott’s (NYSE: ABT) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American College of Cardiology’s 68th Annual Scientific Session (ACC 2019) from March 16 – 18 in New Orleans. The late-breaking studies showcase the depth and breadth of the company’s cardiovascular portfolio, providing new data […]
ABBOTT PARK, Ill., Jan. 23, 2019 /PRNewswire/ — Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2018, and issued financial outlook for 2019. Full-year 2018 worldwide sales of $30.6 billion increased 11.6 percent on a reported basis and 7.3 percent on an organic* basis. Reported diluted EPS from […]
ABBOTT PARK, Ill., Jan. 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib). The approval further expands Abbott’s portfolio of cardiac ablation tools that integrate […]
